Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Stifel lowered its price target on Klaviyo to $35 from $40 with a Buy rating. The firm noted that the company delivered a ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
Asianet Newsable on MSN
Figma Q4 results beat street expectations, so why are analysts slashing targets?
RBC Capital lowered its target on Figma to $31 from $38 and kept a ‘Sector Perform’ rating on the shares, according to TheFly ...
Investor's Business Daily on MSN
IPO stock jumps past buy point on booming preliminary revenue, outlook
The company gave preliminary 2025 results and issued its current-year outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results